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www.cdatm.orgAbstractBerberine (BBR) is a natural alkaloid isolated from the Coptis chinensis. While this plant has been used in Chinese medicine for
more than 2500 years, interest in its effects in treating cardiovascular disease has been growing in the last decade. Recent researches
showed that BBR had the effect of anti-heart failure, anti-hypertension, anti-hyperlipidemia, anti-insulin resistance, anti-
arrhythmias, and anti-platelet aggregation.
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yellow color isolated from the plant Coptis chinensis. It
is widely used in Chinese medicine as an antimicrobial
for treating dysentery and infectious diarrhea.1 While
this plant has been used in Chinese medicine for more
than 2500 years, interest in its effects in treating car-
diovascular disease has been growing in the last
decade. Recent research has shown that berberine has
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platelet aggregation.
Berberine chemical characteristics and
pharmacokinetics
BBR is a plant quaternary ammonium salt from the
group of isoquinoline alkaloids (2, 3-methylenedioxy-
9, 10-dimethoxyprotoberberine chloride; C20H18NO4
þ)
with a molar mass of 336.36122 g/mol (Fig. 1). BBR is
yellow in color, which is why in earlier times Berberis
species were used to dye wool, leather, and wood. As a
natural dye, berberine has a color index of 75160.2
Berberine has low bioavailability and shows poor
absorption through the gut wall (<5%) and bowel P-
glycoprotein appears to contribute to its poor absorp-
tion, actively expelling the alkaloid from the lumen
mucosal cells.3
In a rat noncompartmental model,4 unbound
berberine is transported to bile through active transportElsevier B.V. on behalf of KeAi Communications Co., Ltd. This is an
ons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Chemical structure of berberine.
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liver, with phase I demethylation and phase II glucur-
onidation. Berberine has four main metabolites iden-
tified in rats: berberrubine, thalifendine,
demethyleneberberine and jatrorrhizine (Fig. 1), all of
which have glucuronide conjugates.5 Intestinal bacte-
rial flora takes a role in enterohepatic circulation of
berberine and its conjugated metabolites.4 On the other
hand, a very small amount of unchanged berberine is
eliminated in urine.6 Berberine may inhibit CYP2E1-
like and CYP1A2, which is not related to a signifi-
cant increase in the pharmacological interaction since
most available drugs are not metabolized by these
enzymatic systems.7
Standard doses of berberine are generally well
tolerated and eventual adverse events are rare and mild.
On the contrary, high doses have been associated with
arterial hypotension, dyspnea, flu-like symptoms,
gastrointestinal discomfort, constipation, and cardiac
damage.8 The most studied side effects are those in the
gastrointestinal system. Berberine and derivatives can
also produce gastric lesions.
The safety issue of berberine mostly involves the
risk of some pharmacological interaction. In fact,
berberine displaces bilirubin from albumin about 10-
fold better than phenylbutazone, thus any herb con-
taining large amounts of berberine should be avoided
in jaundiced infants and pregnant woman.9 Berberine
displaces warfarin, thiopental, and tolbutamide fromFig. 2. (A) Berberrubine, C19H16ClNO4; (B) Thalifendine, C19H16NO4; (C)their protein-binding sites, increasing their plasma
levels (Fig. 2).10
Effects of berberine on heart failure
Recent studies suggested that the mechanism of
BBR for improving cardiac function may be related to
increasing the concentration of calcium in cardiac
muscle cells. The augmented cardiac contractile force
is induced by progressively increasing the concen-
tration of cyclic adenosine monophosphate (cAMP) in
cardiac muscle cells by increasing an inward current
carried by calcium ions in the intracellular of cardiac
muscle mediated through alteration of cAMP.11 BBR
increases high energy phosphate in heart failure and
prevented ventricular fibrillation due to its effects on
potassium channels,12,13 increased intracellular cal-
cium,14 and suppressed the delay of depolarization
partly due to sodium influx.15 On the other hand, BBR
has a sympathetic activity-modulated effect on
myocardium. In rats with experimentally induced
cardiac hypertrophy by suprarenal aortic constriction,
BBR decreased plasma noradrenaline and adrenaline
levels and adrenaline in ventricular tissue, improved
cardiac contractility with a shortened time to reach
the maximum rate from the beginning of contraction
and reduced the size of the left ventricular myocar-
dium.16,17 In a dog ischemic heart failure model,
intravenous berberine administration increased car-
diac output, decreased left ventricular end-diastolic
pressure and systemic vascular resistance.18 This ac-
tivity was also confirmed in other animal models.19
Examination of hemodynamic parameters in
humans reveals similar results with an increased car-
diac index, increased left ventricular ejection fraction,
decreased systemic and pulmonary vascular resistance
and left ventricular end-diastolic pressures.20 In a
clinical trial carried out on chronic heart failure pa-
tients, BBR decreased the frequency and complexity of
ventricular premature complexes and increased the left
ventricular ejection fraction.21Demethyleneberberine, C19H18NO4; (D) Jatrorrhizine C20H20ClNO4.
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decreasing cardiovascular through reducing oxidative
stress, low-density lipoprotein (LDL), triglycerides, and
insulin resistance and improving the mood.22 A multi-
center randomized trial showed BBR reduced LDL-c
levels as well as total cholesterol/HDL-c and ApoB/
ApoA1 ratios, while increasing Apo A1, all of which are
improvements in cardiovascular risk indicators.23
Effect of berberine on regulating blood pressure
Systolic and diastolic blood pressures are correlated
with cardiovascular events. A consistent theme in the
literature has confirmed that there is a close correlation
between blood pressure and atherosclerosis.24
BBR can competitively block the a1 receptor of
VSMC, inhibit activity of the cholinphospholipid
enzyme, and enhance the effect of acetylcholine. So
BBR can dilate blood vessels and decrease blood
pressure.25 It is reported that BBR can act on both
endothelium and the underlying vascular smooth
muscle to induce relaxation.19 Nitric oxide released
from endothelium might primarily account for the
BBR-induced endothelium-dependent relaxation,
while activation of 4-aminopyridine and Ba2þ-sensi-
tive Kþ channels, inhibition of intracellar Ca2þ release
from caffeine-sensitive pools, or a direct relaxant effect
are likely responsible for the BBR-induced endothe-
lium-dependent relaxation. Mechanisms related to
either Ca2þ influx or protein kinase C activation may
not be involved. Both vasorelaxant and anti-
proliferative effects may contribute to a long-term
benefit of BBR in the vascular system.
Effects of berberine on regulating blood lipids
In lipid metabolism, the lipid-lowering effect of
BBR appears to be mainly due to the stabilization of
the hepatic LDL-C receptors (LDLR) by an extracel-
lular signal regulated kinase (ERK)-dependent
pathway and also by increasing transcriptional activity
of the LDLR promoter by a c-Jun N terminal kinase
(JNK) pathway.26,27 In addition, in 3T3-L1 cells leptin,
transcription factors like sterol regulatory element
binding protein-1c (SREBP-1c) and CCAAT enhancer-
binding protein-a (C/EBP-a), peroxisome-proliferator
activated receptor-g (PPAR-g), fatty acid synthase,
acetyl-coenzyme A (acetyl-CoA) carboxylase, acyl-
CoA synthase, and lipoprotein lipase are reduced by
berberine treatment.28 Moreover, in addition to LDLR
upregulation, berberine activates 50 adenosine mono-
phosphate (AMP) kinase (AMPK), while blocking themitogen-activated protein kinase (MAPK)/ERK
pathway, resulting in inhibition of lipid synthesis: its
action on AMPK is eliminated by MEK inhibitors,
suggesting a link between these two pathways.29 Other
research showed BBR could counteract hyperlipidemia
partially via upregulating LDLR and apoE mRNA
levels and suppressing HMGR gene expression.30
The antihyperlipidemic effects of BBR have also
been confirmed in humans by some small clinical tri-
als. One study evaluated the effects of 500 mg BBR
twice a day in a hyperlipidemic group of 32 Asian
patients without any other drug use for three months
and compared the results with 11 patients using a
placebo. The BBR significantly reduced the total
cholesterol by 29%, triglycerides by 35%, and LDL-C
by 25%.31 These results have been then confirmed in a
larger trial carried out on 116 hyperlipidemic type 2
diabetic patients randomized to treatment with
berberine 0.5 g thrice daily or a placebo. Beyond a
similar decrease in plasma lipids, the berberine-treated
patients also experienced a significant decrease in
glycohemoglobin, and in both fasting and two-hour
postprandial glucose levels compared with the pla-
cebo group.32
A randomized controlled study provides evidence
that the addition to diet and lifestyle changes of a
patented combination of natural nutraceuticals, based
on red yeast rice extract and berberine, can signifi-
cantly improve the lipid profile versus diet alone in
dyslipidemic subjects in whom a hypolipidemic ther-
apy is not yet indicated or not well tolerated or
contraindicated.33
Effects of berberine on insulin resistance
Beyond a direct effect of berberine on lipid meta-
bolism, recent preclinical and clinical evidence suggest
that it increases insulin receptor expression and im-
proves glucose utility.34
It has been observed that berberine acts as an
insulin-sensitizing agent,35 therefore its activity has
been compared with metformin in different animal
models. In a rat model of type 2 diabetes, berberine
showed better fasting plasma glucose and LDL-C
lowering and better homeostasis model assessment of
insulin resistance (HOMA-IR) than metformin by a
mechanism involving retinol binding protein-4 (RBP-
4) and glucose transporter-4 (GLUT-4).36 However, in
another study, berberine was not inferior to metformin
as an insulin-sensitizer.37
Beyond the large preclinical literature, data on
human glucose metabolism are really preliminary.
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type 2 diabetes, showed that 500 mg of berberine three
times a day was associated with a significant reduction
in hemoglobin-a1 (HbA1) (2%), fasting plasma
glucose (44%), postprandial glucose (45%), fasting
plasma insulin (28%), and HOMA-IR index
(44.7%).38 In this study, berberine also significantly
reduced the plasma total and LDL-C levels. Another
study showed a nutraceutical containing berberine and
chlorogenic acid was able to increase insulin-
sensitivity and liver parameters for the short-term in
overweight patients with mixed hyperlipidemia.39
Berberine anti-arrhythmia effects
Recent studies indicate that BBR may significantly
prolong the duration of the action potential and the
effective refractoriness of the cardiac cells and may
improve cardiac reentry rhythm by modifying the
unidirectional conduction block to a bidirectional
conduction block or delaying the duration of the
reentrant pathway.40 It has been demonstrated that
berberine may protect the cardiac cellular membrane
from interference by hydroxyl radicals and intracel-
lular calcium overload. By its action, BBR may abolish
the delay after depolarization induced by intracellular
calcium overload and may thereby terminate arrhyth-
mias associated with triggered activation.41 In addition,
one study has found that the effects of berberine on
I(K1)/Kir2.1 may be an important mechanism for
producing anti-arrhythmic effects.42 In the
24e48 h ambulatory monitoring of 100 patients with
ventricular tachyarrhythmia, berberine caused a 50%
or greater reduction in ventricular premature contrac-
tions in 62% of patients and a 90% or more reduction
in 38% of patients.43
Berberine anti-platelet aggregation effects
Some studies show that BBR has a significant anti-
platelet effect,44 explained by inhibition of arachidonic
acid metabolism and calcium influx,45 but also by a
partial agonistic effect on plateleta2 adrenoreceptors.
44
BBR inhibited thromboxane synthesis induced by
collagen, adenosine diphosphate and arachidonic acid,
and it might inhibit arachidonic acid metabolism in
platelets and endothelial cells.20 BBR can cause po-
tassium channel blockade resulting in prolongation of
the action potential in cat ventricular monocytes.46 On
the other hand, recent evidence suggests that BBR can
also have prothrombotic effect-enhancing tissue factor
activity.47Conclusion
BBR is usually thought of as a traditional Chinese
medicine, and recent discoveries have provided novel
evidence that it may be considered a promising tool to
counteract cardiovascular disorders. We believe that
after further research, BBR will show a more important
role in the treatment of cardiovascular disease.
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